Effect of microcapsules of luteinizing hormone‐releasing hormone antagonist SB‐75 and somatostatin analog RC‐160 on endocrine status and tumor growth in the dunning R‐3327H rat prostate cancer model
- 1 January 1992
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 20 (4) , 297-310
- https://doi.org/10.1002/pros.2990200405
Abstract
Inhibitory effects of sustained delivery systems (microcapsules) of the modern antagonist of luteinizing hormone‐releasing hormone [Ac‐D‐Nal(2)1, D‐Phe(4Cl)2, D‐Pal(3)3, D‐Cit6, D‐Ala10]LH‐RH (SB‐75) or the potent somatostatin analog D‐Phe‐Cys‐Tyr‐D‐Trp‐Lys‐Val‐Cys‐Trp‐NH2 (RC‐160) were investigated in the Dunning R‐3327H rat prostate cancer model. In the first experiment, the treatment was started 4 months after tumor transplantation, when the tumors measured approximately 2 cm3. Tumor volumes and weights were significantly reduced by SB‐75 microcapsules releasing 48 μg/day or RC‐160 microcapsules releasing 38 μg/day given alone, as compared with the control. The combination of these two analogs showed a synergistic effect. In the second experiment, the treatment was started 7 months after tumor transplantation, when the tumors were well developed and measured about 16 cm3. In addition to a significant reduction in volume, weight, and growth rate of tumors, histological signs of tumor regression were found in the groups treated with SB‐75 microcapsules releasing 72 μg/day given alone or in combination with RC‐160 microcapsules releasing 76 μg/day, but not with RC‐160 alone. No synergistic effect of the combination therapy was found in the second experiment. Serum testosterone levels decreased to undetectable levels and LH levels were also diminished within 2 weeks by administration of SB‐75 alone or in combination with RC‐160. In both experiments, the weights of testes, ventral prostate, and seminal vesicles were greatly reduced by administration of SB‐75 alone or in combination with RC‐160. Our results suggest that the combined therapy with microcapsules of SB‐75 and RC‐160, started soon after the diagnosis of prostate cancer is made, could improve therapeutic response.Keywords
This publication has 29 references indexed in Scilit:
- Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75.Proceedings of the National Academy of Sciences, 1990
- The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptorsBritish Journal of Cancer, 1990
- Release of peptides from sustained delivery systems (microcapsules and microparticles) in vivoInternational Journal of Peptide and Protein Research, 1990
- New antagonists of LHRH II. Inhibition and potentiation of LHRH by closely related analoguesInternational Journal of Peptide and Protein Research, 1988
- Radioimmunoassay for octapeptide analogs of somatostatin: measurement of serum levels after administration of long-acting microcapsule formulations.Proceedings of the National Academy of Sciences, 1988
- Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.Proceedings of the National Academy of Sciences, 1984
- Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.Proceedings of the National Academy of Sciences, 1982
- Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.Proceedings of the National Academy of Sciences, 1981
- Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man.Journal of Clinical Investigation, 1981
- Paradoxical Effects of d-Trp6-Luteinizing Hormone-Releasing Hormone on the Hypothalamic-Pituitary-Gonadal Axis in Immature Female RatsFertility and Sterility, 1979